Bone‐Targeting Agents in Prostate Cancer Care– One Thing That is Underrated in Taiwan

索引

00:00 1.
Bone-Targeting Agents in Prostate Cancer Care - One Thing That Is Underrated in Taiwan
00:52 2.
Drugs to be talked about
01:33 3.
Drugs to be talked about
02:47 4.
Outline
03:03 5.
Outline
03:05 6.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
03:54 7.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
03:55 8.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
04:12 9.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
04:39 10.
Bisphosphonates Embed in Bone And Induce Apoptosis of Activated Osteoclasts
05:02 11.
Denosumab Inhibits RANK Ligand to Interrupt the ‘Vicious Cycle’ of Bone Destruction
05:37 12.
Outline
05:42 13.
Spectrum of Bone Disease in Prostate Cancer
06:19 14.
ADT-Associated Bone Loss
06:58 15.
ADT and Fractures
07:01 16.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
07:02 17.
ADT and Fractures
07:52 18.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
08:40 19.
Alendronate Increases BMD During GnRH Agonist Therapy
09:03 20.
Pamidronate IV Every 3 Mos
09:12 21.
Annual Zoledronic Acid Increases BMD During GnRH Agonist Therapy
09:29 22.
Denosumab Increased BMD at All Skeletal Sites
09:54 23.
Denosumab for Fracture Prevention in Early-Stage Prostate Cancer
09:58 24.
Outline
10:26 25.
Spectrum of Bone Disease in Prostate Cancer
10:38 26.
Consequences of Prostate Cancer Progression on Bone Metastasis
11:11 27.
Time to Bone Metastasis in Non-metastatic CRPC (M0)
11:32 28.
Relationship Between PSADT and Risk for Bone Metastasis or Death
12:04 29.
PR04: Time to Symptomatic Bone Metastases or Prostate Cancer Death
12:18 30.
Denosumab in High-Risk M0 CRPC: BMFS
12:29 31.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
12:45 32.
Denosumab in High-Risk M0 CRPC: BMFS
12:49 33.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
13:02 34.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 4 Mos
13:20 35.
Outline
13:22 36.
Spectrum of Bone Disease in Prostate Cancer
13:38 37.
Skeletal-Related Events and Clinical Consequences of Bone Metastases
14:07 38.
Bone Metastases Can result in Serious and Debilitating Skeletal-Related Events (SREs)
14:20 39.
PR05: Symptomatic Bone PFS
14:57 40.
Time to First SRE: Zoledronate vs Placebo
15:31 41.
Zoledronic Acid Studies Primary Endpoint: SRE
15:51 42.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
16:06 43.
Zoledronic Acid Studies Primary Endpoint: SRE
16:07 44.
Time to First SRE: Zoledronate vs Placebo
16:08 45.
Zoledronic Acid Studies Primary Endpoint: SRE
16:08 46.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
16:39 47.
Denosumab vs ZOL in CRPC: No Effect on Overall Disease Progression and Survival
17:09 48.
ALSYMPCA: Overall Survival
17:50 49.
Outline
17:54 50.
Characteristics of Antiresorptive Agents Used for Patients with Prostate Cancer
18:34 51.
Preventing and Managing Hypocalcaemia
19:48 52.
藥物使用前的評估是否能接受BPs或Dmab的使用?
21:21 53.
藥物使用中如何預防顎骨壞死的產生?
21:51 54.
Outline
21:55 55.
Bone-Targeting Agents in Taiwan
22:38 56.
Guidelines for Management of Bone Metastases in Prostate Cancer
23:30 57.
Outline
23:32 58.
Incremental benefits of bone resorption inhibitors
24:36 59.
Summary of Phase III Trials Investigating the Use of Antiresorptive Drugs
26:08 60.
Thank you for your attention!
26:45 61.
Summary of Phase III Trials Investigating the Use of Antiresorptive Drugs
26:46 62.
Incremental benefits of bone resorption inhibitors
26:46 63.
Outline
26:47 64.
Guidelines for Management of Bone Metastases in Prostate Cancer
26:47 65.
Bone-Targeting Agents in Taiwan
26:48 66.
Outline
26:48 67.
藥物使用中如何預防顎骨壞死的產生?
26:48 68.
藥物使用前的評估是否能接受BPs或Dmab的使用?
26:49 69.
Preventing and Managing Hypocalcaemia
26:49 70.
Characteristics of Antiresorptive Agents Used for Patients with Prostate Cancer
26:53 71.
Outline
26:54 72.
ALSYMPCA: Overall Survival
26:54 73.
Denosumab vs ZOL in CRPC: No Effect on Overall Disease Progression and Survival
26:55 74.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
26:55 75.
Zoledronic Acid Studies Primary Endpoint: SRE
27:07 76.
Time to First SRE: Zoledronate vs Placebo
29:39 77.
PR05: Symptomatic Bone PFS
29:39 78.
Bone Metastases Can result in Serious and Debilitating Skeletal-Related Events (SREs)
29:40 79.
Skeletal-Related Events and Clinical Consequences of Bone Metastases
29:40 80.
Spectrum of Bone Disease in Prostate Cancer
29:41 81.
Outline
29:41 82.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 4 Mos
29:42 83.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
29:43 84.
Denosumab in High-Risk M0 CRPC: BMFS
29:43 85.
PR04: Time to Symptomatic Bone Metastases or Prostate Cancer Death
29:44 86.
Relationship Between PSADT and Risk for Bone Metastasis or Death
29:44 87.
Time to Bone Metastasis in Non-metastatic CRPC (M0)
29:45 88.
Consequences of Prostate Cancer Progression on Bone Metastasis
29:45 89.
Spectrum of Bone Disease in Prostate Cancer
29:46 90.
Outline
29:46 91.
Denosumab for Fracture Prevention in Early-Stage Prostate Cancer
29:47 92.
Denosumab Increased BMD at All Skeletal Sites
29:48 93.
Annual Zoledronic Acid Increases BMD During GnRH Agonist Therapy
29:48 94.
Pamidronate IV Every 3 Mos
29:49 95.
Alendronate Increases BMD During GnRH Agonist Therapy
29:49 96.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
29:50 97.
ADT and Fractures
29:51 98.
ADT-Associated Bone Loss
29:51 99.
Spectrum of Bone Disease in Prostate Cancer
29:52 100.
Outline
29:53 101.
Denosumab Inhibits RANK Ligand to Interrupt the ‘Vicious Cycle’ of Bone Destruction
29:54 102.
Bisphosphonates Embed in Bone And Induce Apoptosis of Activated Osteoclasts
29:54 103.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
29:55 104.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
29:55 105.
Outline
29:56 106.
Outline
29:57 107.
Drugs to be talked about

筆記 (0)

未登入或權限不足!

討論

00:00 1.
Bone-Targeting Agents in Prostate Cancer Care - One Thing That Is Underrated in Taiwan
00:52 2.
Drugs to be talked about
01:33 3.
Drugs to be talked about
02:47 4.
Outline
03:03 5.
Outline
03:05 6.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
03:54 7.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
03:55 8.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
04:12 9.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
04:39 10.
Bisphosphonates Embed in Bone And Induce Apoptosis of Activated Osteoclasts
05:02 11.
Denosumab Inhibits RANK Ligand to Interrupt the ‘Vicious Cycle’ of Bone Destruction
05:37 12.
Outline
05:42 13.
Spectrum of Bone Disease in Prostate Cancer
06:19 14.
ADT-Associated Bone Loss
06:58 15.
ADT and Fractures
07:01 16.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
07:02 17.
ADT and Fractures
07:52 18.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
08:40 19.
Alendronate Increases BMD During GnRH Agonist Therapy
09:03 20.
Pamidronate IV Every 3 Mos
09:12 21.
Annual Zoledronic Acid Increases BMD During GnRH Agonist Therapy
09:29 22.
Denosumab Increased BMD at All Skeletal Sites
09:54 23.
Denosumab for Fracture Prevention in Early-Stage Prostate Cancer
09:58 24.
Outline
10:26 25.
Spectrum of Bone Disease in Prostate Cancer
10:38 26.
Consequences of Prostate Cancer Progression on Bone Metastasis
11:11 27.
Time to Bone Metastasis in Non-metastatic CRPC (M0)
11:32 28.
Relationship Between PSADT and Risk for Bone Metastasis or Death
12:04 29.
PR04: Time to Symptomatic Bone Metastases or Prostate Cancer Death
12:18 30.
Denosumab in High-Risk M0 CRPC: BMFS
12:29 31.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
12:45 32.
Denosumab in High-Risk M0 CRPC: BMFS
12:49 33.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
13:02 34.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 4 Mos
13:20 35.
Outline
13:22 36.
Spectrum of Bone Disease in Prostate Cancer
13:38 37.
Skeletal-Related Events and Clinical Consequences of Bone Metastases
14:07 38.
Bone Metastases Can result in Serious and Debilitating Skeletal-Related Events (SREs)
14:20 39.
PR05: Symptomatic Bone PFS
14:57 40.
Time to First SRE: Zoledronate vs Placebo
15:31 41.
Zoledronic Acid Studies Primary Endpoint: SRE
15:51 42.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
16:06 43.
Zoledronic Acid Studies Primary Endpoint: SRE
16:07 44.
Time to First SRE: Zoledronate vs Placebo
16:08 45.
Zoledronic Acid Studies Primary Endpoint: SRE
16:08 46.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
16:39 47.
Denosumab vs ZOL in CRPC: No Effect on Overall Disease Progression and Survival
17:09 48.
ALSYMPCA: Overall Survival
17:50 49.
Outline
17:54 50.
Characteristics of Antiresorptive Agents Used for Patients with Prostate Cancer
18:34 51.
Preventing and Managing Hypocalcaemia
19:48 52.
藥物使用前的評估是否能接受BPs或Dmab的使用?
21:21 53.
藥物使用中如何預防顎骨壞死的產生?
21:51 54.
Outline
21:55 55.
Bone-Targeting Agents in Taiwan
22:38 56.
Guidelines for Management of Bone Metastases in Prostate Cancer
23:30 57.
Outline
23:32 58.
Incremental benefits of bone resorption inhibitors
24:36 59.
Summary of Phase III Trials Investigating the Use of Antiresorptive Drugs
26:08 60.
Thank you for your attention!
26:45 61.
Summary of Phase III Trials Investigating the Use of Antiresorptive Drugs
26:46 62.
Incremental benefits of bone resorption inhibitors
26:46 63.
Outline
26:47 64.
Guidelines for Management of Bone Metastases in Prostate Cancer
26:47 65.
Bone-Targeting Agents in Taiwan
26:48 66.
Outline
26:48 67.
藥物使用中如何預防顎骨壞死的產生?
26:48 68.
藥物使用前的評估是否能接受BPs或Dmab的使用?
26:49 69.
Preventing and Managing Hypocalcaemia
26:49 70.
Characteristics of Antiresorptive Agents Used for Patients with Prostate Cancer
26:53 71.
Outline
26:54 72.
ALSYMPCA: Overall Survival
26:54 73.
Denosumab vs ZOL in CRPC: No Effect on Overall Disease Progression and Survival
26:55 74.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
26:55 75.
Zoledronic Acid Studies Primary Endpoint: SRE
27:07 76.
Time to First SRE: Zoledronate vs Placebo
29:39 77.
PR05: Symptomatic Bone PFS
29:39 78.
Bone Metastases Can result in Serious and Debilitating Skeletal-Related Events (SREs)
29:40 79.
Skeletal-Related Events and Clinical Consequences of Bone Metastases
29:40 80.
Spectrum of Bone Disease in Prostate Cancer
29:41 81.
Outline
29:41 82.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 4 Mos
29:42 83.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
29:43 84.
Denosumab in High-Risk M0 CRPC: BMFS
29:43 85.
PR04: Time to Symptomatic Bone Metastases or Prostate Cancer Death
29:44 86.
Relationship Between PSADT and Risk for Bone Metastasis or Death
29:44 87.
Time to Bone Metastasis in Non-metastatic CRPC (M0)
29:45 88.
Consequences of Prostate Cancer Progression on Bone Metastasis
29:45 89.
Spectrum of Bone Disease in Prostate Cancer
29:46 90.
Outline
29:46 91.
Denosumab for Fracture Prevention in Early-Stage Prostate Cancer
29:47 92.
Denosumab Increased BMD at All Skeletal Sites
29:48 93.
Annual Zoledronic Acid Increases BMD During GnRH Agonist Therapy
29:48 94.
Pamidronate IV Every 3 Mos
29:49 95.
Alendronate Increases BMD During GnRH Agonist Therapy
29:49 96.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
29:50 97.
ADT and Fractures
29:51 98.
ADT-Associated Bone Loss
29:51 99.
Spectrum of Bone Disease in Prostate Cancer
29:52 100.
Outline
29:53 101.
Denosumab Inhibits RANK Ligand to Interrupt the ‘Vicious Cycle’ of Bone Destruction
29:54 102.
Bisphosphonates Embed in Bone And Induce Apoptosis of Activated Osteoclasts
29:54 103.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
29:55 104.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
29:55 105.
Outline
29:56 106.
Outline
29:57 107.
Drugs to be talked about

分享
- Facebook
- Twitter
- LinkedIn
- 嵌入網址
- QR code

索引
筆記
討論
全螢幕

Bone‐Targeting Agents in Prostate Cancer Care– One Thing That is Underrated in Taiwan

長度: 32:21, 瀏覽: 821, 最近修訂: 2017-05-19

00:00 1.
Bone-Targeting Agents in Prostate Cancer Care - One Thing That Is Underrated in Taiwan
00:52 2.
Drugs to be talked about
01:33 3.
Drugs to be talked about
02:47 4.
Outline
03:03 5.
Outline
03:05 6.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
03:54 7.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
03:55 8.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
04:12 9.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
04:39 10.
Bisphosphonates Embed in Bone And Induce Apoptosis of Activated Osteoclasts
05:02 11.
Denosumab Inhibits RANK Ligand to Interrupt the ‘Vicious Cycle’ of Bone Destruction
05:37 12.
Outline
05:42 13.
Spectrum of Bone Disease in Prostate Cancer
06:19 14.
ADT-Associated Bone Loss
06:58 15.
ADT and Fractures
07:01 16.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
07:02 17.
ADT and Fractures
07:52 18.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
08:40 19.
Alendronate Increases BMD During GnRH Agonist Therapy
09:03 20.
Pamidronate IV Every 3 Mos
09:12 21.
Annual Zoledronic Acid Increases BMD During GnRH Agonist Therapy
09:29 22.
Denosumab Increased BMD at All Skeletal Sites
09:54 23.
Denosumab for Fracture Prevention in Early-Stage Prostate Cancer
09:58 24.
Outline
10:26 25.
Spectrum of Bone Disease in Prostate Cancer
10:38 26.
Consequences of Prostate Cancer Progression on Bone Metastasis
11:11 27.
Time to Bone Metastasis in Non-metastatic CRPC (M0)
11:32 28.
Relationship Between PSADT and Risk for Bone Metastasis or Death
12:04 29.
PR04: Time to Symptomatic Bone Metastases or Prostate Cancer Death
12:18 30.
Denosumab in High-Risk M0 CRPC: BMFS
12:29 31.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
12:45 32.
Denosumab in High-Risk M0 CRPC: BMFS
12:49 33.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
13:02 34.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 4 Mos
13:20 35.
Outline
13:22 36.
Spectrum of Bone Disease in Prostate Cancer
13:38 37.
Skeletal-Related Events and Clinical Consequences of Bone Metastases
14:07 38.
Bone Metastases Can result in Serious and Debilitating Skeletal-Related Events (SREs)
14:20 39.
PR05: Symptomatic Bone PFS
14:57 40.
Time to First SRE: Zoledronate vs Placebo
15:31 41.
Zoledronic Acid Studies Primary Endpoint: SRE
15:51 42.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
16:06 43.
Zoledronic Acid Studies Primary Endpoint: SRE
16:07 44.
Time to First SRE: Zoledronate vs Placebo
16:08 45.
Zoledronic Acid Studies Primary Endpoint: SRE
16:08 46.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
16:39 47.
Denosumab vs ZOL in CRPC: No Effect on Overall Disease Progression and Survival
17:09 48.
ALSYMPCA: Overall Survival
17:50 49.
Outline
17:54 50.
Characteristics of Antiresorptive Agents Used for Patients with Prostate Cancer
18:34 51.
Preventing and Managing Hypocalcaemia
19:48 52.
藥物使用前的評估是否能接受BPs或Dmab的使用?
21:21 53.
藥物使用中如何預防顎骨壞死的產生?
21:51 54.
Outline
21:55 55.
Bone-Targeting Agents in Taiwan
22:38 56.
Guidelines for Management of Bone Metastases in Prostate Cancer
23:30 57.
Outline
23:32 58.
Incremental benefits of bone resorption inhibitors
24:36 59.
Summary of Phase III Trials Investigating the Use of Antiresorptive Drugs
26:08 60.
Thank you for your attention!
26:45 61.
Summary of Phase III Trials Investigating the Use of Antiresorptive Drugs
26:46 62.
Incremental benefits of bone resorption inhibitors
26:46 63.
Outline
26:47 64.
Guidelines for Management of Bone Metastases in Prostate Cancer
26:47 65.
Bone-Targeting Agents in Taiwan
26:48 66.
Outline
26:48 67.
藥物使用中如何預防顎骨壞死的產生?
26:48 68.
藥物使用前的評估是否能接受BPs或Dmab的使用?
26:49 69.
Preventing and Managing Hypocalcaemia
26:49 70.
Characteristics of Antiresorptive Agents Used for Patients with Prostate Cancer
26:53 71.
Outline
26:54 72.
ALSYMPCA: Overall Survival
26:54 73.
Denosumab vs ZOL in CRPC: No Effect on Overall Disease Progression and Survival
26:55 74.
Time to First On-Study SRE: Denosumab vs Zoledronic Acid
26:55 75.
Zoledronic Acid Studies Primary Endpoint: SRE
27:07 76.
Time to First SRE: Zoledronate vs Placebo
29:39 77.
PR05: Symptomatic Bone PFS
29:39 78.
Bone Metastases Can result in Serious and Debilitating Skeletal-Related Events (SREs)
29:40 79.
Skeletal-Related Events and Clinical Consequences of Bone Metastases
29:40 80.
Spectrum of Bone Disease in Prostate Cancer
29:41 81.
Outline
29:41 82.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 4 Mos
29:42 83.
Bone Metastasis–Free Survival in Patients With PSADT ≤ 6 Mos
29:43 84.
Denosumab in High-Risk M0 CRPC: BMFS
29:43 85.
PR04: Time to Symptomatic Bone Metastases or Prostate Cancer Death
29:44 86.
Relationship Between PSADT and Risk for Bone Metastasis or Death
29:44 87.
Time to Bone Metastasis in Non-metastatic CRPC (M0)
29:45 88.
Consequences of Prostate Cancer Progression on Bone Metastasis
29:45 89.
Spectrum of Bone Disease in Prostate Cancer
29:46 90.
Outline
29:46 91.
Denosumab for Fracture Prevention in Early-Stage Prostate Cancer
29:47 92.
Denosumab Increased BMD at All Skeletal Sites
29:48 93.
Annual Zoledronic Acid Increases BMD During GnRH Agonist Therapy
29:48 94.
Pamidronate IV Every 3 Mos
29:49 95.
Alendronate Increases BMD During GnRH Agonist Therapy
29:49 96.
Higher Death Rate Observed at 36 Mos in Pts With Vertebral Fracture at Study Entry
29:50 97.
ADT and Fractures
29:51 98.
ADT-Associated Bone Loss
29:51 99.
Spectrum of Bone Disease in Prostate Cancer
29:52 100.
Outline
29:53 101.
Denosumab Inhibits RANK Ligand to Interrupt the ‘Vicious Cycle’ of Bone Destruction
29:54 102.
Bisphosphonates Embed in Bone And Induce Apoptosis of Activated Osteoclasts
29:54 103.
A Vicious Cycle of Bone Destruction May Develop in the Presence of Tumour Cells
29:55 104.
RANK Ligand Is An Essential Mediator of Osteoclast Formation, Function and Survival
29:55 105.
Outline
29:56 106.
Outline
29:57 107.
Drugs to be talked about

位置

資料夾名稱

2015臺大攝護祭-醫藥護人員場

發表人

系統管理者

單位

泌尿部

建立

2017-05-19 16:56:16

最近修訂

2017-05-19 18:59:21

長度

32:21